Keyword: janet-marchibroda
BPC Issue Brief Supports New Guidance by U.S. Patent and Trademark Office on Therapeutic Antibodies
BPC releases new issue brief that examines the patent policies governing therapeutic antibodies that can target a particular disease state.
Janet Marchibroda & Joel White: Doctors Are Drowning in Data Entry as Health IT Policy Lags
With the renaissance in health technology has come growing pains.
Health IT Now, BPC, and Leading Health Care and Technology Groups Promote New Vision for Health IT Policy
Health IT Now and BPC releases a report calling for a more modern health IT and digital health framework that assures consumer protections.
Passage of FDA Reauthorization Act is Important Milestone for Patients
Congress took an important step to bring safe and effective treatments and cures to patients by passing the Food and Drug Administration (FDA) Reauthorization Act of 2017.
Cybersecurity and Medical Devices: Risk Assessment and Response
Join us to examine cybersecurity risks associated with medical device technology and the strategies and policies that can help address such risks.
Improving Patient Safety and Information Technology Calls for Greater Leadership, Collaboration, and a Systems-Based Approach
BPC’s new report outlines recommendations for improving health IT’s role in providing safer care for patients while promoting innovation.
Senate HELP Committee’s Passage of Bipartisan FDA Reauthorization Important Milestone for Patients
The Bipartisan Policy Center applauds the Senate HELP Committee for passing the Food and Drug Administration Reauthorization Act of 2017.
Patient Safety and Information Technology
IT plays a key role in preventing many medical errors by offering clinical decision support and better communication between clinicians and patients.
FDA User Fees are Critical to Bringing Safe, Effective Cures to Patients
User fees play a critical role in providing the FDA the resources it needs to maintain the gold standard in both the review and approval of drugs
We can improve and modernize the drug development process
The bigger concern is the fact that it takes more than ten years and $2 billion to develop a new drug from a molecule to a medicine.
Dialogue: Staying Connected
